Story

MacroGenics Shares Rise After Gilead Exercises Option, Triggering $10M Payment

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20261 min read
MacroGenics Shares Rise After Gilead Exercises Option, Triggering $10M Payment
Text size
Background

Shares of MacroGenics Inc. (NASDAQ:MGNX) climbed 4.3% in after-hours trading on Tuesday after Gilead Sciences opted to exercise its license for a preclinical bispecific antibody program, triggering a $10 million payment to the company.

Details of the Agreement

The exercised option grants Gilead Sciences an exclusive license to a preclinical program targeting two undisclosed solid tumor targets. According to the announcement, the program utilizes MacroGenics’ proprietary TRIDENT platform, which is designed to create antibody-based therapeutics.

This development is part of a broader collaboration agreement established between the two companies in 2022. The partnership is focused on advancing novel cancer treatments and includes a total of three programs.

Sample IUX Markets – In-articleAd

Broader Collaboration and Financial Outlook

Beyond the newly licensed program, the collaboration includes another preclinical bispecific program and MGD024, a clinical-stage CD123 × CD3 bispecific DART molecule. The exercise of the option signals progress within the partnership and provides MacroGenics with non-dilutive capital.

For investors, the long-term potential of the alliance remains significant. MacroGenics is eligible to receive up to approximately $1.6 billion in additional payments contingent on achieving future development, regulatory, and commercial milestones. The company is also entitled to receive royalties on worldwide net sales of any products that result from the collaboration.

Read next

More on Stocks
Back to latest news

LATEST